SCHEMBL24468331

SCHEMBL24468331

Cc1nn(C)c2c1c(N)nc1cnc(C(=O)O)cc12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
MAP4K1 Q92918 3/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
RCE1 Q9Y256 1/20 0.32
HCAR2 Q8TDS4 1/20 0.31
KDM4E B2RXH2 3/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
APOBEC3A P31941 1/20 0.31
PRMT5 O14744 1/20 0.31
KCNH2 Q12809 1/20 0.31
PIM3 Q86V86 2/20 0.31
DAPK3 O43293 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24468457 0.80 TDP1 (0.46) KDM4EALDH1A1POLBGAAAPOBEC3A
SCHEMBL24468462 0.79 MAP4K1 (0.35) IKBKETBK1MAP4K1HCAR2KDM4E
SCHEMBL24468327 0.77 IKBKE (0.36) IKBKETBK1RCE1KDM4EALDH1A1
SCHEMBL27198277 0.76 PI4KA (0.34) IKBKETBK1MAP4K1HCAR2KDM4E
Hydrochloric Acid SCHEMBL29196277 0.75 TDP1 (0.34) RCE1KDM4EALDH1A1POLBAPOBEC3A
SCHEMBL24540936 0.74 HCAR2 (0.35) IKBKETBK1MAP4K1HCAR2KDM4E
SCHEMBL30887534 0.74 TLR7 (0.44) ALDH1A1GAA
SCHEMBL23757451 0.67 PRMT5 (0.51) HCAR2KDM4EALDH1A1POLBGAA
Lithium Ion SCHEMBL31513921 0.67 PI4KA (0.33) MAP4K1
Hydrochloric Acid SCHEMBL31137261 0.67 ASPH (0.31) KDM4EPRMT5KCNH2GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251624-B1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC (US) 2025-10-29 EP disclosed
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS AMGEN INC. (US) 2024-04-18 US disclosed
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. 2024-03-28 US disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 IKBKE 1202/4885TBK1 1611/4885MAP4K1 866/4885
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 IKBKE 1243/4885TBK1 1722/4885MAP4K1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.